Potential New Drug Therapy for Crohn's Disease, University of California, San Diego (UCSD) Study
Published: Oct 18, 2012
Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn’s Disease, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the October 18, 2012 issue of the New England Journal of Medicine (NEJM). Results from the clinical trial showed ustekinumab (Stelara) increased clinical response and remission in patients suffering from moderate-to-severe Crohn’s Disease — a form of inflammatory bowel disease (IBD) that can lead to a variety of distressing symptoms, including diarrhea, intestinal bleeding and weight loss. Serious complications such as bowel obstruction and abscesses can also occur.